Longeveron Inc. LGVN
Regular-session close
After hours · Nov 20, 4:00 PM ET
- YTD
- -67.19%
- 1 year
- -72.47%
5D -0.98 (-31.72%)
- Market cap
- 5.60M
- Revenue (ttm)
- 1.23M
- EPS (ttm)
- -7.95
- Shares out
- 13.35M
- Forward P/E
- -1.16
- YTD return
- -67.19%
- 1-year return
- -72.47%
- 50-day average
- 2.01
- Volume
- 27.26K
- Avg volume
- 116.15K
- Open
- 1.83
- Previous close
- 1.82
- Day's range
- 1.64 – 1.83
- 52-week range
- 1.31 – 12.30
- Beta
- 0.35
- Price target
- 8.88 (+434.6%)
Key statistics
- 200-day average
- 2.26
- Enterprise value
- 22.40M
- Price / sales
- 21.37
- Price / book
- 0.66
- Revenue growth
- 115.70%
- Free cash flow
- -10.03M
- Total cash
- 12.38M
- Total debt
- 1.75M
- Return on equity
- -142.16%
- Short % of float
- 10.24%
Fundamental scorecard
6 of 25 checks passed on LGVN’s reported financials
6of 25 checks passed
- Value 2 of 5
- Growth 1 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | -0.53 | -0.34 | +0.19 | +35.85% |
| Aug 14, 2024 | Jun 1, 2024 | -1.03 | -1.83 | -0.80 | -77.67% |
| Aug 14, 2024 | Jun 1, 2024 | -1.03 | — | — | — |
| May 14, 2024 | Mar 1, 2024 | -2.01 | -1.61 | +0.40 | +19.90% |
| May 14, 2024 | Mar 1, 2024 | -2.01 | — | — | — |
| Feb 27, 2024 | Dec 1, 2023 | -2.10 | -2.50 | -0.40 | -19.05% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 5, 2024 | Roth MKM | init | — | Buy |
| Nov 25, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 4, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 4, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 27, 2024 | Maxim Group | main | Buy | Buy |
| Aug 15, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About Longeveron Inc.
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer's disease, and hypoplastic left heart syndrome. Longeveron Inc. was incorporated in 2014 and is headquartered in Miami, Florida.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- longeveron.com
News
12 Health Care Stocks Moving In Tuesday's After-Market Session
12 Health Care Stocks Moving In Tuesday's Intraday Session Longeveron Announces Its ELPIS II Study Of Laromestrocel Failed To Meet Primary Efficacy Endpoint Of Change From Baseline In Right Ventricular Ejection Fraction To Treat Infants With Hypoplastic Left Heart Syndrome
12 Health Care Stocks Moving In Thursday's After-Market Session
Your note
Sign in to keep a note on LGVN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| AGAFONOVA NATALIYA | Officer | Stock Award(Grant) | Aug 14, 2024 | 163,130 |
| BALUCH KHOSO | Director | Sale | Dec 1, 2024 | 23,750 |
| HARE JOSHUA M | Officer, Director and Beneficial Owner | Stock Award(Grant) | Aug 14, 2024 | 727,046 |
| HARE NEIL E | Director | Stock Award(Grant) | Aug 14, 2024 | 30,246 |
| HASHAD MOHAMED WA'EL AHMED | Chief Executive Officer | Stock Award(Grant) | Aug 14, 2024 | 90,368 |
| KENDER RICHARD N | Director | Stock Award(Grant) | May 9, 2024 | 16,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Geode Capital Management, LLC | 0.97% | 128,947 | 228.24K | Sep 29, 2024 |
| Vanguard Group Inc | 0.34% | 44,984 | 79.62K | Sep 29, 2024 |
| Capital Investment Advisory Services, LLC | 0.20% | 26,525 | 46.95K | Sep 29, 2024 |
| State Street Corporation | 0.11% | 15,180 | 26.87K | Sep 29, 2024 |
| Creative Planning | 0.08% | 11,200 | 19.82K | Sep 29, 2024 |
| Blackrock Inc. | 0.08% | 10,016 | 17.73K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity Extended Market Index Fund | 0.54% | 72,197 | 127.79K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.34% | 44,984 | 79.62K | Sep 29, 2024 |
| Fidelity Total Market Index Fund | 0.18% | 24,137 | 42.72K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.13% | 17,087 | 30.24K | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.03% | 3,572 | 6.32K | Oct 30, 2024 |
